公司背景 - CRISPR Therapeutics是一家专注于为严重疾病创造转变性基因药物的生物制药公司[1] - 公司高管团队将在2024年2月21日参加Citi 2024虚拟肿瘤领导峰会[1] 公司发展 - CRISPR Therapeutics自成立以来，已从一个在基因编辑领域推进项目的研究阶段公司转变为一个在包括血红蛋白病、肿瘤学、再生医学、心血管和罕见疾病等广泛疾病领域拥有多样化产品候选组合的公司[3] 合作关系 - 公司与拜耳和维康制药等领先公司建立战略合作伙伴关系[3]

公司业绩预测 - CRISPR Therapeutics AG (CRSP) 预计在2023年12月报告的季度业绩中，盈利将同比增长，收入也将增加[1] - 分析师们认为，如果关键数字超出预期，公司股价可能会上涨，反之则可能下跌[2] - 分析师们对公司未来盈利预期的持续性主要取决于管理层在财报电话会议上对业务状况的讨论，值得注意的是正面每股收益（EPS）惊喜的概率[3]

- Led by new investor EcoR1 Capital and SR One with participation from existing and new investors - - Well positioned to execute on our on-going clinical trials in oncology, cardiovascular and diabetes, and further accelerate our auto-immune and in vivo gene writing programs - - Further strengthens balance sheet with pro forma cash position >$2.1 billion - ZUG, Switzerland and BOSTON, Feb. 13, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transfo ...

—Over 8,000 patients 12 years of age and older with severe SCD or TDT may be eligible for treatment— ZUG, Switzerland and BOSTON, Feb. 13, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced today that the European Commission has granted conditional marketing authorization to CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene edited therapy. CASGEVY is approved for the t ...

公司股价表现 - CRISPR Therapeutics AG (CRSP) 最新收盘价为$70.01，较前一天上涨了+1.71% [1] - 公司股价在过去一个月内上涨了6.15%，超过了医疗行业的2.05%和标普500指数的5.07% [2] 收益预期和分析 - 分析师和投资者将密切关注CRISPR Therapeutics AG即将披露的收益情况，预计公司将报告每股收益为-$0.21，较去年同期增长了85.11% [3] - 分析师对公司业务和盈利能力持乐观态度，这种积极的估算调整反映了分析师对公司未来的乐观看法 [4] Zacks Rank模型和行业排名 - 研究表明，估算调整与即将到来的股价表现直接相关，公司开发了Zacks Rank模型，该模型考虑了这些估算变化并提供了可操作的评级系统 [5] - Zacks Rank系统从1（强烈买入）到5（强烈卖出），自1988年以来，1股票的平均年度收益率为+25%，CRISPR Therapeutics AG目前的Zacks Rank为3（持有） [6] 行业表现和交易建议 - 医疗-生物医学和遗传学行业属于医疗行业，该行业的Zacks Industry Rank为103，位于所有250多个行业的前41% [7] - 个别行业群体的实力由Zacks Industry Rank衡量，该排名根据这些群体内个别股票的平均Zacks Rank计算，研究显示，排名前50%的行业的表现超过排名后50%的行业 [8] - 在即将到来的交易会话中，请记得使用Zacks.com关注这些以及更多影响股价的指标 [9]

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $64.75, moving +0.12% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 1.07%. Elsewhere, the Dow saw an upswing of 0.35%, while the tech-heavy Nasdaq appreciated by 1.74%. The company's shares have seen an increase of 4.41% over the last month, surpassing the Medical sector's gain of 4.02% and the S&P 500's gain of 2.93%. The investment community will be paying close attention to the earnings ...

医疗保健股票市场 - 医疗保健股票在2024年有很大的增长空间[1] - 医疗行业因全球对健康和福祉的关注而增长[1] - 医疗股票将再次引起买家的兴趣，因为他们认识到该行业产生巨大利润的潜力[3] Vertex Pharmaceuticals（VRTX） - Vertex Pharmaceuticals（VRTX）在2024年医疗股票市场上取得了重大进展[5] - Vertex Pharmaceuticals在疼痛治疗方面取得了巨大进展[6] - Vertex Pharmaceuticals正在扩大其产品组合，成为2024年医疗股票市场上的重要参与者[7] CRISPR Therapeutics（CRSP） - CRISPR Therapeutics因其开创性的基因治疗工作而备受关注[9] - CRISPR Therapeutics在与Vertex合作开发糖尿病治疗方面取得了重要进展[12] Illumina（ILMN） - Illumina在基因测序方面取得了重大突破，成为2024年医疗股票市场上的重要参与者[13] - Illumina的战略联盟显示了其在医学研究领域的重要性[14] - Illumina在全球医疗模式变革中扮演着重要角色[15]

公司背景 - CRISPR Therapeutics去年股价上涨54%，朝着重要里程碑迈进[1] - CRISPR Therapeutics专注于基因编辑，利用CRISPR技术修复导致某些疾病的有缺陷基因[3] - CRISPR Therapeutics的首个产品获得监管批准，显示监管机构愿意批准CRISPR基因编辑产品，只要临床数据强有力[4]

It finally happened. About 10 years after being created, gene-editing specialist CRISPR Therapeutics (CRSP 1.46%) earned approval for its first therapy late last year. The treatment in question is called Casgevy and targets sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), two blood-related diseases. This regulatory development was a significant milestone for CRISPR, but the biotech will need more clinical and regulatory success in the years ahead to keep investors happy. Can CRISP ...

With CRISPR Therapeutics (CRSP 5.28%) in the news thanks to its successful work in developing cutting- edge gene therapies, it's easy to assume that everything in the business is going swimmingly. Between the fruits of its ongoing commercialization process and a quickly expanding development pipeline, it's certainly true that it has more than one opportunity at impressing the market and enriching its shareholders. Still, even the most successful companies experience setbacks from time to time, and this biot ...